Avalon Investment & Advisory’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $21M | Sell |
253,084
-137,937
| -35% | -$11.4M | 0.57% | 50 |
|
|
2022
Q4 | $33.6M | Sell |
391,021
-683,314
| -64% | -$54.1M | 0.96% | 31 |
|
|
2022
Q3 | $66.3M | Sell |
1,074,335
-18,888
| -2% | -$1.19M | 2.05% | 6 |
|
|
2022
Q2 | $67.6M | Sell |
1,093,223
-2,964
| -0.3% | -$184K | 1.91% | 7 |
|
|
2022
Q1 | $65.2M | Buy |
1,096,187
+56,764
| +5% | +$3.63M | 1.57% | 9 |
|
|
2021
Q4 | $75.5M | Sell |
1,039,423
-121,886
| -10% | -$8.4M | 1.86% | 8 |
|
|
2021
Q3 | $81.1M | Buy |
1,161,309
+6,819
| +0.6% | +$479K | 1.88% | 7 |
|
|
2021
Q2 | $79.5M | Buy |
1,154,490
+433,661
| +60% | +$29M | 1.76% | 12 |
|
|
2021
Q1 | $46.6M | Buy |
720,829
+54,174
| +8% | +$3.49M | 1.07% | 30 |
|
|
2020
Q4 | $38.8M | Sell |
666,655
-91,046
| -12% | -$5.49M | 0.79% | 38 |
|
|
2020
Q3 | $47.9M | Sell |
757,701
-66,330
| -8% | -$4.6M | 1.06% | 23 |
|
|
2020
Q2 | $63.4M | Sell |
824,031
-48,839
| -6% | -$3.74M | 1.46% | 13 |
|
|
2020
Q1 | $65.3M | Sell |
872,870
-159,993
| -15% | -$11.1M | 1.67% | 10 |
|
|
2019
Q4 | $67.1M | Buy |
1,032,863
+521,727
| +102% | +$34M | 1.37% | 13 |
|
|
2019
Q3 | $32.4M | Buy |
511,136
+25,183
| +5% | +$1.65M | 0.72% | 39 |
|
|
2019
Q2 | $32.8M | Buy |
485,953
+34,217
| +8% | +$2.25M | 0.73% | 36 |
|
|
2019
Q1 | $29.4M | Sell |
451,736
-137,102
| -23% | -$9.11M | 0.67% | 43 |
|
|
2018
Q4 | $36.8M | Buy |
588,838
+19,048
| +3% | +$1.33M | 0.95% | 26 |
|
|
2018
Q3 | $44M | Buy |
569,790
+83,524
| +17% | +$6.31M | 1.24% | 16 |
|
|
2018
Q2 | $34.4M | Buy |
486,266
+122,332
| +34% | +$8.64M | 1.02% | 19 |
|
|
2018
Q1 | $27.4M | Buy |
363,934
+51,569
| +17% | +$4.1M | 0.85% | 30 |
|
|
2017
Q4 | $22.4M | Sell |
312,365
-3,947
| -1% | -$300K | 0.7% | 44 |
|
|
2017
Q3 | $25.6M | Buy |
316,312
+18,576
| +6% | +$1.42M | 0.82% | 35 |
|
|
2017
Q2 | $21.1M | Buy |
297,736
+203,112
| +215% | +$13.5M | 0.7% | 41 |
|
|
2017
Q1 | $6.43M | Sell |
94,624
-3,997
| -4% | -$281K | 0.22% | 133 |
|
|
2016
Q4 | $7.06M | Buy |
98,621
+2,626
| +3% | +$195K | 0.25% | 112 |
|
|
2016
Q3 | $7.59M | Sell |
95,995
-3,708
| -4% | -$301K | 0.29% | 108 |
|
|
2016
Q2 | $8.32M | Sell |
99,703
-108,012
| -52% | -$9.59M | 0.32% | 99 |
|
|
2016
Q1 | $19.1M | Sell |
207,715
-14,734
| -7% | -$1.33M | 0.83% | 44 |
|
|
2015
Q4 | $22.5M | Sell |
222,449
-15,536
| -7% | -$1.62M | 0.97% | 33 |
|
|
2015
Q3 | $23.4M | Buy |
237,985
+12,368
| +5% | +$1.37M | 1.03% | 32 |
|
|
2015
Q2 | $26.4M | Buy |
225,617
+6,139
| +3% | +$671K | 1.14% | 20 |
|
|
2015
Q1 | $21.5M | Buy |
219,478
+11,343
| +5% | +$1.15M | 0.94% | 32 |
|
|
2014
Q4 | $19.6M | Buy |
208,135
+18,539
| +10% | +$1.92M | 0.89% | 37 |
|
|
2014
Q3 | $20.2M | Buy |
189,596
+5,453
| +3% | +$534K | 1.02% | 26 |
|
|
2014
Q2 | $15.3M | Buy |
184,143
+15,595
| +9% | +$1.21M | 0.77% | 41 |
|
|
2014
Q1 | $11.9M | Sell |
168,548
-3,416
| -2% | -$268K | 0.66% | 55 |
|
|
2013
Q4 | $12.9M | Buy |
171,964
+1,368
| +0.8% | +$95.3K | 0.72% | 48 |
|
|
2013
Q3 | $10.7M | Sell |
170,596
-65,709
| -28% | -$3.93M | 0.69% | 49 |
|
|
2013
Q2 | $12.1M | Buy |
+236,305
| New | +$12.3M | 0.72% | 46 |
|
Other funds holding GILD
Avalon Investment & Advisory's GILD Position: Q1 2023 in Review
Avalon Investment & Advisory reduced its Gilead Sciences (GILD) stake by 35% in Q1 2023, selling an estimated $11.4M and leaving 253,084 shares worth $21M. The position accounts for 0.57% of the portfolio, ranked #50.
Avalon Investment & Advisory first reported a position in GILD in Q2 2013 and has held it in 40 quarters since. The position peaked at $81.1M in Q3 2021. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.
- Avalon Investment & Advisory held 253,084 shares of Gilead Sciences worth $21M as of Q1 2023.
- Avalon Investment & Advisory sold 137,937 Gilead Sciences shares in Q1 2023, an estimated $11.4M.
- Gilead Sciences made up 0.57% of Avalon Investment & Advisory's portfolio in Q1 2023, its #50 holding.
- Avalon Investment & Advisory first reported a position in Gilead Sciences in Q2 2013 and has held it in 40 quarters since.
- Avalon Investment & Advisory's Gilead Sciences position peaked at $81.1M in Q3 2021.
- 1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.
Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.